Bridge Pharma Inc.

Dfb Soria, LLC

Medivir Ab

Oriel Therapeutics, Inc.

Lakewood Amedex, Inc.

Meritage Pharma, Inc.

Hallux Inc.

Epigenesis Pharmaceuticals, Inc.

Tetralogic Shape UK Ltd

Mical Pharmaceuticals Llc—h Series, A Series Of Mical Pharmaceuticals Llc, A Multi-Division Limited Liability Company

Respirks, Inc.

Nycomed US Inc.

Altana Inc.

Lipidio Pharmaceuticals Inc.

Viropharma Biologics LLC

Keith Johnson

Robert Lathrop

Todd W Chappell

Roland Franke

Holly Maulhardt

Meidong Yang

A K Gunnar Aberg

Steven A Kates

Anthony James Hickey

Bruce S Ferris

Jeffrey Alan Warden

William Myles Riley

Timothy M Crowder

Ak Gunnar Aberg

Jay Kinsley Fording

Michael Duane Garten

Sean Anderson

Paul Gilbert Rockwell

Mark Ennis Ketner

Nigel R A Beeley

Karl F Popp

Charles Rodney Greenaway Evans

Robert A Casper

David L Gardner

Malcolm Hill

Elaine Phillips

Vincent B Ciofalo

Jay E Birnbaum

Cynthia Licalsi

Frances Furr Kelly

Rukmini Rajagopalan

Gordon J Dow

Sherry A Leonard

Hemant Deshmukh

Kieran George Mooney

J Gordon Foulkes

Howard G Welgus

Celia P Jenkinson

Gel formulations having antimicrobial activity are disclosed. Methods of using the gel formulation are further disclosed.

Bisphosphocin gel formulations and uses thereof

Pharmaceutical carriers which provide an environment of physical and chemical stability comprising a therapeutically effective amount of an active pharmaceutical ingredient (API) compound of structure I, one or more antioxidants, one or more chelators and a vehicle base comprising water and one or more pharmaceutically acceptable non-aqueous solvents, one or more absorption enhancers, one or more gelling agents and one or more pH buffering agents are described.

Methods of treating a patient afflicted with non-alcoholic steatohepatitis (NASH)

A pharmaceutical composition, comprising a therapeutically effective amount of an active pharmaceutical ingredient (API) compound represented by the following structural formula 

Pharmaceutical formulation for histone deacetylase inhibitors

A hydrophobic topical skin composition is disclosed. The composition includes greater than 50% w/w of the composition of a continuous hydrophobic carrier, 5-24% w/w of one or more volatile silicone fluids, and 0.1 to 5% w/w of the composition of a plurality of taxane nanoparticles, wherein the mean particle size (number) of the taxane nanoparticles is from 0.1 microns to 1.5 microns, and wherein the taxane nanoparticles are crystalline nanoparticles or a combination of amorphous and crystalline nanoparticles.

Delivery of drug nanoparticles and methods of use thereof

Gel formulations including a Bisphosphocin having antimicrobial activity are disclosed. Methods of using the gel formulations including a Bisphosphocin are further disclosed.

Disclosed are compositions and methods useful for enhancing the skin penetration of drug nanoparticles. The compositions can be hydrophobic and include a hydrophobic carrier, a volatile silicone fluid, and drug nanoparticles. Also disclosed are methods for inhibiting crystal growth of drug nanoparticles in an aqueous carrier or a hydrophobic carrier. Further, methods to topically treat psoriasis using compositions containing nanoparticles of paclitaxel or other taxanes are disclosed.

Disclosed herein are methods of treating a mammal in need of a reduction in intraocular pressure by administering an intraocular formulation including a therapeutically effective amount of norketotifen for the reduction of intraocular pressure to the eye of the mammal in need thereof, wherein the intraocular formulation includes about 0.02 wt % to about 1.0 wt % norketotifen or a salt or an isomer thereof, calculated as the norketotifen free base. In certain aspects, the intraocular formulation is free from any added preservative and the intraocular formulation is self-preserving. Also included herein is a method of treating a human in need of a reduction in intraocular pressure by administering an intranasal formulation that includes a therapeutically effective amount of norketotifen for the reduction of intraocular pressure to the eye of the human in need thereof. Also, the beneficial effects of known drugs for high IOP are improved by co-administration with norketotifen.

Formulations and methods for treating high intraocular pressure

A pharmaceutical composition, comprising a therapeutically effective amount of an active pharmaceutical ingredient (API) compound represented by the following structural formula at least one acidifying agent; and a vehicle base comprising at least one pharmaceutically acceptable non-aqueous solvent. Values and preferred values of the variables in structural formula (I) are defined herein. 

Provided herein are methods for treating, preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.

Corticosteroid compositions

Ophthalmic compositions containing norketotifen and methods of making the same and the use thereof are disclosed. The methods also comprise administering to the eyes of a mammal in need thereof topical ophthalmic compositions containing norketotifen.

Ocular formulations of norketotifen

Storage stable, topical lotion compositions for treating corticosteroid-responsive dermatoses are provided by the present invention which include a halobetasol material comprising halobetasol or its pharmaceutically acceptable salts, esters, and solvates; and a pharmaceutically acceptable carrier which includes: (a) one or more fatty alcohols and/or one or more alkoxylated fatty alcohols, (b) one or more polyol humectants, and (c) diisopropyl adipate. Storage stable, topical lotion compositions for treating corticosteroid-responsive dermatoses are provided by the present invention which include 0.05% halobetasol propionate; and a pharmaceutically acceptable carrier which includes: (a) one or more fatty alcohols and/or one or more alkoxylated fatty alcohols, (b) one or more polyol humectants, and (c) diisopropyl adipate.

Topical steroid composition and method

Self-preserving ophthalmic formulations containing norketotifen and methods of making the same and the use thereof in patients suffering from xerophthalmia are disclosed. The methods also comprise administering to the eyes of a mammal in need thereof, self-preserving topical ophthalmic formulations containing norketotifen, free from any added preservative.

Methods of treatment of xerophthalmia with self-preserving ocular formulations of norketotifen

Methods of using a cycloheptathiophene compound for the treatment of xerophthalmia are described, as are formulations and compositions for such treatment.

Treating xerophthalmia with norketotifen

Growing community of inventors

Durham, NC, United States of America

Keith Johnson